Document is current
Any future updates will be listed below
-
Authors
Cestari, Tania F. https://orcid.org/0000-0003-3001-0202
Souza, Cacilda da Silva https://orcid.org/0000-0002-8157-7658
Azulay-Abulafia, Luna https://orcid.org/0000-0002-4698-2009
Romiti, Ricardo https://orcid.org/0000-0003-0165-3831
Carvalho, André V.E. https://orcid.org/0000-0002-0407-538X
Silva de Castro, Caio César https://orcid.org/0000-0001-9767-5765
Marques, Sílvio Alencar https://orcid.org/0000-0002-5512-4700
Antonio, João Roberto https://orcid.org/0000-0002-0268-5934
Fabrício, Lincoln https://orcid.org/0000-0001-9191-1085
Soliman, Ahmed M. https://orcid.org/0009-0008-8632-1396
Wu, Tianshuang https://orcid.org/0009-0007-4205-9579
Sinvhal, Ranjeeta https://orcid.org/0009-0003-1950-9181
Stakias, Vassilis https://orcid.org/0009-0006-2628-0399
Song, Alexandra P. https://orcid.org/0000-0002-8344-6651
Kalabic, Jasmina https://orcid.org/0009-0007-4698-1042
Martin, Naomi https://orcid.org/0009-0006-9169-8791
Oyafuso, Luiza Keiko Matsuka https://orcid.org/0000-0003-3982-3322
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
Journal Title: Anais Brasileiros de Dermatologia
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2024.08.002
Content Type: article
Copyright: © 2024 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.
